Keros Therapeutics, Inc.KROSNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +4750.00% | +2027.27% | +254413.25% | +49002.70% | +3575.77% |
| Gross Profit Growth | +0.00% | +1795.10% | +254413.25% | +48002.70% | +18639.19% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +21.69% | +33.90% | +37.74% | +12.49% | +12.52% |
| Weighted Average Shares Diluted Growth | +21.69% | +33.90% | +39.30% | +12.49% | +12.52% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +114.14% | +308.43% | +989.65% | +1218.88% | +189.39% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +77.56% | +66.44% | +61.49% | +66.40% | +28.23% |
| Book Value per Share Growth | +48.01% | +28.49% | +16.57% | +49.26% | +17.35% |
| Debt Growth | +34.73% | +30.58% | +29.63% | +28.64% | -9.63% |
| R&D Expense Growth | +44.19% | +21.71% | +27.32% | +7.38% | -60.35% |
| SG&A Expenses Growth | +14.23% | +17.13% | +1.83% | +45.39% | +3.13% |